Literature DB >> 10716920

Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.

G Barbato1, D O Cicero, F Cordier, F Narjes, B Gerlach, S Sambucini, S Grzesiek, V G Matassa, R De Francesco, R Bazzo.   

Abstract

Few structures of viral serine proteases, those encoded by the Sindbis and Semliki Forest viruses, hepatitis C virus (HCV) and cytomegalovirus, have been reported. In the life cycle of HCV a crucial role is played by a chymotrypsin-like serine protease encoded at the N-terminus of the viral NS3 protein, the solution structure of which we present here complexed with a covalently bound reversible inhibitor. Unexpectedly, the residue in the P2 position of the inhibitor induces an effective stabilization of the catalytic His-Asp hydrogen bond, by shielding that region of the protease from the solvent. This interaction appears crucial in the activation of the enzyme catalytic machinery and represents an unprecedented observation for this family of enzymes. Our data suggest that natural substrates of this serine protease could contribute to the enzyme activation by a similar induced-fit mechanism. The high degree of similarity at the His-Asp catalytic site region between HCV NS3 and other viral serine proteases suggests that this behaviour could be a more general feature for this category of viral enzymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716920      PMCID: PMC305661          DOI: 10.1093/emboj/19.6.1195

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

1.  Conservation and variability in the structures of serine proteinases of the chymotrypsin family.

Authors:  A M Lesk; W D Fordham
Journal:  J Mol Biol       Date:  1996-05-10       Impact factor: 5.469

2.  A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond.

Authors:  C S Cassidy; J Lin; P A Frey
Journal:  Biochemistry       Date:  1997-04-15       Impact factor: 3.162

3.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

4.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

5.  Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications.

Authors:  J F Bazan; R J Fletterick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  15N NMR spectroscopy of hydrogen-bonding interactions in the active site of serine proteases: evidence for a moving histidine mechanism.

Authors:  W W Bachovchin
Journal:  Biochemistry       Date:  1986-11-18       Impact factor: 3.162

7.  Protonation-state dependence of hydrogen bond strengths and exchange rates in a serine protease catalytic triad: bovine chymotrypsinogen A.

Authors:  J L Markley; W M Westler
Journal:  Biochemistry       Date:  1996-08-27       Impact factor: 3.162

8.  Stereospecific nuclear magnetic resonance assignments of the methyl groups of valine and leucine in the DNA-binding domain of the 434 repressor by biosynthetically directed fractional 13C labeling.

Authors:  D Neri; T Szyperski; G Otting; H Senn; K Wüthrich
Journal:  Biochemistry       Date:  1989-09-19       Impact factor: 3.162

9.  Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.

Authors:  P Ingallinella; S Altamura; E Bianchi; M Taliani; R Ingenito; R Cortese; R De Francesco; C Steinkühler; A Pessi
Journal:  Biochemistry       Date:  1998-06-23       Impact factor: 3.162

10.  The refined 2.2-A (0.22-nm) X-ray crystal structure of the ternary complex formed by bovine trypsinogen, valine-valine and the Arg15 analogue of bovine pancreatic trypsin inhibitor.

Authors:  W Bode; J Walter; R Huber; H R Wenzel; H Tschesche
Journal:  Eur J Biochem       Date:  1984-10-01
View more
  10 in total

1.  Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.

Authors:  Howard J Worman; Feng Lin
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

2.  Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.

Authors:  Christopher T Lemke; Nathalie Goudreau; Songping Zhao; Oliver Hucke; Diane Thibeault; Montse Llinàs-Brunet; Peter W White
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

3.  The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.

Authors:  Annarita Casbarra; Fabrizio Dal Piaz; Paolo Ingallinella; Stefania Orrù; Piero Pucci; Antonello Pessi; Elisabetta Bianchi
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

4.  Measurement of homonuclear three-bond J(H(N)Halpha) coupling constants in unlabeled peptides complexed with labeled proteins: application to a decapeptide inhibitor bound to the proteinase domain of the NS3 protein of hepatitis C virus (HCV).

Authors:  D O Cicero; G Barbato; U Koch; P Ingallinella; E Bianchi; S Sambucini; P Neddermann; R De Francesco; A Pessi; R Bazzo
Journal:  J Biomol NMR       Date:  2001-05       Impact factor: 2.835

5.  Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation.

Authors:  Pornwaratt Niyomrattanakit; Pakorn Winoyanuwattikun; Santad Chanprapaph; Chanan Angsuthanasombat; Sakol Panyim; Gerd Katzenmeier
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection.

Authors:  G V Gregorio; K Choudhuri; Y Ma; P Pensati; R Iorio; P Grant; J Garson; D P Bogdanos; A Vegnente; G Mieli-Vergani; D Vergani
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  Structure and dynamics of coxsackievirus B4 2A proteinase, an enyzme involved in the etiology of heart disease.

Authors:  Nicola J Baxter; Andreas Roetzer; Hans-Dieter Liebig; Svetlana E Sedelnikova; Andrea M Hounslow; Tim Skern; Jonathan P Waltho
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Probing contacts of inhibitor locked in transition states in the catalytic triad of DENV2 type serine protease and its mutants by 1H, 19F and 15 N NMR spectroscopy.

Authors:  Peter Agback; Esmeralda Woestenenk; Tatiana Agback
Journal:  BMC Mol Cell Biol       Date:  2020-05-25

9.  Probing the Dynamic Structure-Function and Structure-Free Energy Relationships of the Coronavirus Main Protease with Biodynamics Theory.

Authors:  Hongbin Wan; Vibhas Aravamuthan; Robert A Pearlstein
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-06

10.  The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.

Authors:  Hamzah A Hamad; Jeremy Thurston; Thomas Teague; Edward Ackad; Mohammad S Yousef
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.